US › Healthcare

Corbus Pharmaceuticals Holding (CRBP)

US · Healthcare · Biotechnology

$9.40+5.38%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-23.0M
Profit YoY
-35.3%
EPS
$-1.23
EPS estimate
$-1.22

EPS came in at -1.23 against a street estimate of -1.22 — a miss of 0.8%.

Key statistics

Market cap
$166.2M
Forward P/E
0.0
P/B
1.32
Book value
$7.12
EPS (TTM)
$-5.74
52-week high
$20.56
52-week low
$7.12
50-day MA
$8.69
200-day MA
$9.80
Beta
2.56

Analyst view

Analysts rate Corbus Pharmaceuticals Holding a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $35.30.

Shareholding

Insiders
1.08%
Institutions
71.10%

Largest institutional holders

FundStake
Cormorant Asset Management, LLC12.66%
Orbimed Advisors, LLC9.38%
Aberdeen Group PLC7.13%
Vanguard Capital Management, LLC3.96%
Citadel Advisors Llc3.92%
Prosight Management, LP3.76%
Diadema Partners LP2.37%
Stonepine Capital Management Llc2.07%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Corbus Pharmaceuticals Holding — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.